ALLRHealthcare · Biotechnology

ALLR Stock Forecast: Allarity Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026

$0.98

−0.10% on the day

The 1 Wall Street analysts covering Allarity Therapeutics, Inc. hold a median 12-month price target of $11 — +1017.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 7 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$15.8M

Ticker Nerd rank

30 / 100

Median analyst target

$11

Analysts covering

Revenue$0.0

Operating income−$2.7M

Net income−$3.4M

Free cash flow−$2.6M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−6.3%

−30.7%

YTD

−8.9%

−43.8%

From 52W high

−44.4%

From 52W low

+21.5%

$0.81

$1.77

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

ALLR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Allarity Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Oct 2026

30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Growth

Momentum

Quality

Volatility

Accruals

Value

Issuance

Size (89): Smaller than most of the companies we track.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALLR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALLR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $11Median $11High $11

The green dot is the last close — the median target sits +1017.9% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
16 Sept 2026	Ascendiant Capital	Maintains	Buy	$10 → $11
16 Sept 2026	Ascendiant Capital	Maintains	Buy	—
8 June 2026	Ascendiant Capital	Maintains	Buy	—
8 June 2026	Ascendiant Capital	Maintains	Buy	$9.75 → $10
10 Apr 2026	Ascendiant Capital	Maintains	Buy	—
9 Dec 2025	Ascendiant Capital	Maintains	Buy	—
26 Sept 2025	Ascendiant Capital	Maintains	Buy	—
28 July 2025	Ascendiant Capital	Initiates	Buy	—
23 Aug 2022	Ladenburg Thalmann	Downgrade	Neutral	—
27 May 2022	Ladenburg Thalmann	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALLR appears on the weeks it earns a place.

Performance

ALLR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Allarity Therapeutics, Inc. returned −43.8% against +17.4% for the S&P 500, dividends included.

ALLR vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALLR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Allarity Therapeutics, Inc. (ALLR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 0.1×
Price / sales: 45.4×
Price / book: 4.4×
EV / EBITDA: −2.0×

Growth & margins

Revenue growth (YoY): −100.0%
Earnings growth (YoY): —
Gross margin: —
Operating margin: −3129.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −157.1%
Return on assets: −25.3%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Allarity Therapeutics, Inc. (ALLR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Allarity Therapeutics, Inc. has a market value of $15.8M and an enterprise value of $21.2M.
Revenue in the twelve months to 30 June 2026: $345K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$12.3M, a −3575.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$13.8M.
Allarity Therapeutics, Inc. spent $887K on share buybacks in the twelve months to 30 June 2026.
Shares outstanding: 15.8M.
Trailing P/E: 0.1×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Allarity Therapeutics, Inc. employs 7 people — $49K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

ALLR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
ALLRAllarity Therapeutics, Inc.	$15.8M	30
AEONAEON Biopharma, Inc.	$15.5M	52
PTNPalatin Technologies, Inc.	$16.2M	38
NCELNewCelX Ltd.	$16.2M	4
BCDABioCardia, Inc.	$16.2M	41
DAREDaré Bioscience, Inc.	$15.3M	31
ICUSeastar Medical Holding Corp.	$16.4M	24

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Allarity Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALLR news & analysis

Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib's Clinical Development

GlobeNewsWire · 30 Sept 2026positive

Allarity Therapeutics provided an update on recent advances in its Drug Response Predictor (DRP) technology, patent portfolio, and in-house laboratory capabilities that aim to strengthen stenoparib's clinical development and expand external partnership opportunities, including newly awarded patents supporting DRP use for commercial exclusivity of stenoparib.

Why it matters — A stock watcher would care because these intellectual-property and capability advances could reinforce Allarity's competitive position and enhance the development and partnership potential of its lead candidate stenoparib.

Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research

GlobeNewsWire · 28 Sept 2026positive

Allarity Therapeutics announced it has expanded its laboratory capabilities to include proteomics and cell line research, which will support deeper mechanism-of-action research for its drug candidate stenoparib. The new capabilities are also intended to broaden Allarity's research offerings to enable external partnerships.

Why it matters — An ALLR watcher would care because the expanded research capabilities signal strengthened in-house R&D for stenoparib and a potential new avenue for collaboration and revenue through external partnerships.

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

GlobeNewsWire · 15 Sept 2026positive

Allarity Therapeutics announced that the Japan Patent Office has granted a patent covering the company's proprietary stenoparib-specific Drug Response Predictor (DRP) companion diagnostic. The patent is intended to further strengthen the development of stenoparib, Allarity's dual PARP and WNT pathway inhibitor in Phase 2 clinical development.

Why it matters — For ALLR watchers, this granted Japanese patent expands intellectual-property protection for the stenoparib companion diagnostic and reinforces the company's development position.

Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement

GlobeNewsWire · 11 Sept 2026neutral

Allarity Therapeutics announced that its newly formed special purpose acquisition company, Allarity Acquisition Corp., has publicly filed a Registration Statement on Form S-1 with the SEC relating to a proposed initial public offering of its units.

Why it matters — ALLR watchers would care because the SPAC filing represents a strategic capital allocation move that could provide additional funding for the company's development of stenoparib.

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

GlobeNewsWire · 14 Aug 2026positive

Allarity Therapeutics reported financial results for the second quarter ended June 30, 2026, and announced completion of its Phase 3-ready stenoparib manufacturing campaign. The company closed the quarter with $26.9 million in cash and restricted cash, was awarded a key U.S. patent protecting stenoparib exclusivity into 2042, reported AACR 2026 data linking higher stenoparib DRP scores with enhanced overall survival in advanced ovarian cancer, and obtained CLIA certification for its in-house laboratory to support U.S. clinical trials.

Why it matters — The results signal forward clinical and manufacturing progress for stenoparib, including patent protection into 2042, cash to sustain operations, and infrastructure to advance DRP-guided trials.

FAQ

Frequently asked questions about ALLR stock

What is the ALLR stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Allarity Therapeutics, Inc. have a median 12-month price target of $11, with estimates ranging from $11 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALLR stock a buy right now?

Of the 1 analysts covering Allarity Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Allarity Therapeutics, Inc. 30 out of 100 across roughly 4,600 US stocks as at 7 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALLR?

As at 7 Oct 2026, Allarity Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will ALLR stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1017.9% from the last close, and Ticker Nerd's factor model ranks Allarity Therapeutics, Inc. 30 out of 100 as at 7 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALLR stock forecast for 2030?

No analyst covering Allarity Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALLR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $11 over the next 12 months.

How has ALLR stock performed over the past year?

Allarity Therapeutics, Inc. returned -43.8% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Allarity Therapeutics, Inc. do?

Allarity Therapeutics Inc. is a clinical-stage precision medicine biopharmaceutical company focused on developing personalized cancer treatments.

What is the latest news on ALLR?

The most recent item we track (GlobeNewsWire, 30 Sept 2026): "Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib's Clinical Development". Allarity Therapeutics provided an update on recent advances in its Drug Response Predictor (DRP) technology, patent portfolio, and in-house laboratory capabilities that aim to strengthen stenoparib's clinical development and expand external partnership opportunities, including newly awarded patents supporting DRP use for commercial exclusivity of stenoparib.

Company

About Allarity Therapeutics, Inc.

Allarity Therapeutics Inc. is a clinical-stage precision medicine biopharmaceutical company focused on developing personalized cancer treatments. Its current work centers on stenoparib, an investigational therapy being studied for advanced recurrent ovarian cancer, alongside its proprietary Drug Response Predictor technology, which is designed to help identify patients most likely to benefit from specific oncology drugs. The company also supports a limited portfolio of additional cancer-focused programs and companion diagnostics intended to improve treatment selection and clinical decision-making. Allarity Therapeutics operates primarily in the oncology and drug development segments, with activities in the United States and Denmark. As a specialist in biomarker-guided cancer care, the company occupies a niche role in the broader pharmaceutical market by combining therapeutic development with diagnostic tools to support more targeted treatment approaches.

CEO Mr. Thomas H. Jensen · 7 employees · United States · https://www.allarity.com